Compare · LLY vs SKYE
LLY vs SKYE
Side-by-side comparison of Eli Lilly and Company (LLY) and Skye Bioscience Inc. (SKYE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and SKYE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.09T, about 151908.0x SKYE ($7.2M).
- LLY has been more active in the news (21 items in the past 4 weeks vs 4 for SKYE).
- LLY has more recent analyst coverage (25 ratings vs 8 for SKYE).
- Company
- Eli Lilly and Company
- Skye Bioscience Inc.
- Price
- $1188.30+2.68%
- $1.64-4.37%
- Market cap
- $1.09T
- $7.2M
- 1M return
- +5.76%
- -
- 1Y return
- +40.85%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 21
- 4
- Recent ratings
- 25
- 8
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest LLY
- Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions
- Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL
- Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease
- Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
- 3 Biotech Stocks Throwing Their Weight Around, and Another that Wants to Help You Lose Yours
- Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes
- New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis
- Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
- Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison
- Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison
Latest SKYE
- Director Schwab Andrew J. sold $239,555 worth of shares (148,079 units at $1.62) (SEC Form 4)
- Large owner 5am Partners Vii, Llc sold $239,555 worth of shares (148,079 units at $1.62) (SEC Form 4)
- Director Schwab Andrew J. sold $64,734 worth of shares (33,892 units at $1.91) (SEC Form 4)
- Large owner 5am Partners Vii, Llc sold $64,734 worth of shares (33,892 units at $1.91) (SEC Form 4)
- SEC Form DEFA14A filed by Skye Bioscience Inc.
- Skye Bioscience Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Leadership Update, Other Events
- SEC Form DEFA14A filed by Skye Bioscience Inc.
- Skye Bioscience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Director Schwab Andrew J. sold $140,313 worth of shares (375,840 units at $0.37) (SEC Form 4)
- Large owner 5am Partners Vii, Llc sold $140,313 worth of shares (375,840 units at $0.37) (SEC Form 4)